切换至 "中华医学电子期刊资源库"

中华实验和临床感染病杂志(电子版) ›› 2016, Vol. 10 ›› Issue (04) : 385 -391. doi: 10.3877/cma.j.issn.1674-1358.2016.04.001

临床论著

替诺福韦酯对照阿德福韦酯初治的中国慢性乙型肝炎患者48周的随机、双盲、对照研究
杨松1, 邢卉春1, 于岩岩2, 曹建彪3, 陈良4, 陆伟5, 李旭6, 陈新月7, 杨永平8, 汪茂荣9, 申保生10, 成军1,()   
  1. 1. 100015 北京,首都医科大学附属北京地坛医院肝病中心
    2. 100034 北京,北京大学第一医院感染疾病科
    3. 100700 北京,陆军总医院全军肝病治疗中心
    4. 201508 上海,复旦大学附属公共卫生临床中心肝炎一科
    5. 300192 天津,天津市第二人民医院天津市肝病医学研究所
    6. 230022 合肥市,安徽医科大学第一附属医院感染科
    7. 100069 北京,首都医科大学附属北京佑安医院肝病综合科
    8. 100853 北京,中国人民解放军第三〇二医院肝脏肿瘤诊疗与研究中心
    9. 210002 南京市,解放军第81医院全军肝病中心
    10. 453100 新乡市,新乡医学院第一附属医院感染疾病科
  • 收稿日期:2016-02-27 出版日期:2016-08-15
  • 通信作者: 成军
  • 基金资助:
    北京市卫生系统高层次卫生技术人才培养计划(No. 2015-3-108); 北京市医院管理局临床医学发展专项经费资助(No. ZY201402); 首都卫生发展科研专项项目(No.首发2014-2-2172)

Tenofovir disoproxil fumarate vs. adefovir dipivoxil in Chinese treatment naive patients with chronic hepatitis B for 48 weeks: a randomized, double-blinded, controlled study

Song Yang1, Huichun Xing1, Yanyan Yu2, Jianbiao Cao3, Liang Chen4, Wei Lu5, Xu Li6, Xinyue Chen7, Yongping Yang8, Maorong Wang9, Baosheng Shen10, Jun Cheng1,()   

  1. 1. Center of Liver Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China
    2. Department of Infectious Diseases, Peking University The First Hospital, Beijing 100034, China
    3. Therapy Center for Liver Diseases, Chinese People’s Liberation Army General Hospital, Beijing 100700, China
    4. First Department of Hepatitis, Public Health Clinical Center of Fudan University, Shanghai 201508, China
    5. Institute of Liver Diseases, Tianjin Second People’s Hospital, Tianjin 300192, China
    6. Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China
    7. Department of Liver Disease, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
    8. Liver Tumor Diagnosis, Treatment and Research Center, 302 Hospital of PLA, Beijing 100039, China
    9. Center for Liver Diseases, The 81st Hospital of PLA, Nanjing 210002, China
    10. Department of Infectious Diseases, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
  • Received:2016-02-27 Published:2016-08-15
  • Corresponding author: Jun Cheng
引用本文:

杨松, 邢卉春, 于岩岩, 曹建彪, 陈良, 陆伟, 李旭, 陈新月, 杨永平, 汪茂荣, 申保生, 成军. 替诺福韦酯对照阿德福韦酯初治的中国慢性乙型肝炎患者48周的随机、双盲、对照研究[J/OL]. 中华实验和临床感染病杂志(电子版), 2016, 10(04): 385-391.

Song Yang, Huichun Xing, Yanyan Yu, Jianbiao Cao, Liang Chen, Wei Lu, Xu Li, Xinyue Chen, Yongping Yang, Maorong Wang, Baosheng Shen, Jun Cheng. Tenofovir disoproxil fumarate vs. adefovir dipivoxil in Chinese treatment naive patients with chronic hepatitis B for 48 weeks: a randomized, double-blinded, controlled study[J/OL]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2016, 10(04): 385-391.

目的

明确国产替诺福韦酯治疗中国慢性乙型肝炎患者的疗效与安全性。

方法

本研究采取多中心、随机、双盲、阳性对照的研究设计,选择阿德福韦酯为对照。研究的主要疗效指标为治疗48周HBV DNA< 20 IU/ml患者比率;另外,评价患者治疗48周HBV DNA下降水平、ALT复常率、HBsAg阴转及血清学转换率以及HBeAg阳性患者HBeAg阴转及血清学转换率。并评价替诺福韦酯与阿德福韦酯治疗组患者的不良事件的发生等情况。

结果

共入组患者267例,其中替诺福韦酯治疗组(TDF组)141例,阿德福韦酯治疗组(ADV组)139例。两组患者基线人口学指标与临床指标差异均无统计学意义(P均> 0.05)。HBeAg阳性患者中,TDF组患者HBV DNA < 20 IU/ml患者比率显著高于ADV组患者(55.3% vs. 20.0%;χ2= 20.750,P < 0.001);同样在HBeAg阳性患者中,TDF组患者HBV DNA < 20 IU/ml患者比率显著高于ADV组患者(86.2%% vs. 62.7%%;χ2= 20.750,P = 0.003)。ALT复常率在HBeAg阳性(84.5% vs. 80.5%;χ2= 0.406,P = 0.524)与阴性CHB患者(84.2% vs. 80.7%;χ2= 0.243,P = 0.622)组中差异均无统计学意义。HBeAg阳性组患者TDF组与ADV组的HBeAg阴转率(5.6% vs. 12.8%;χ2= 2.335,P = 0.126)和HBsAg阴转率(1.4% vs. 3.8%;χ2= 0.182,P = 0.670)差异均无统计学意义。HBeAg阴性组患者无HBsAg阴转病例。TDF组与ADV组患者不良事件和不良反应发生率差异均无统计学意义(P均> 0.05)。

结论

国产TDF制剂治疗中国HBeAg阳性和阴性的CHB患者抑制HBV效果优于ADV且安全耐受性良好,可作为我国CHB患者的抗病毒治疗首选方案之一。

Objective

To evaluate the efficacy and safety profiles of tenofovir disoproxil fumarate (TDF) vs. adefovir dipivoxil (ADV) for Chinese patients with chronic hepatitis B (CHB).

Methods

In this randomized, double-blind, controlled study, patients with CHB received TDF or ADV (ratio for 1︰1) once daily for 48 weeks were assigned, randomly. The primary efficacy end point was plasma HBV DNA level < 20 IU/ml at week 48. The levels of HBV DNA decrease, ratios of ALT normalization, HBsAg loss and seroconversion and HBeAg loss and seroconversion, while the adverse events and adverse effects were also compared between patients in TDF group and ADV group.

Results

Total of 267 patients were enrolled, among whom, there were 141 patients in TDF group and 139 patients in ADV group. The baseline characteristics were comparable between the two groups (P all > 0.05). At week 48, virological responses occurred in more HBeAg positive patients with TDF treatment than patients with ADV treatment (55.3% vs. 20.0%; χ2= 20.750, P < 0.001) and in more HBeAg negative patients with TDF treatment than patients receiving ADV treatment (86.2% vs. 62.7%; χ2= 20.750, P = 0.003). There were no significant difference in ratio of ALT normalization in both HBeAg positive (84.5% vs. 80.5%; χ2= 0.406, P = 0.524) and negative groups (84.2% vs. 80.7%; χ2= 0.243, P = 0.622). In HBeAg positive group, there were no significant difference in ratio of HBeAg loss (5.6% vs. 12.8%; χ2= 2.335, P = 0.126) and HBsAg loss (1.4% vs. 3.8%; χ2= 0.182, P = 0.670). No case in HBeAg negative group lost HBsAg after 48 weeks therapy. Safety profiles including incidence of adverse events and adverse effects were compared between TDF and ADV groups with no significant difference (P all > 0.05).

Conclusions

Among Chinese CHB patients with HBeAg positive and negative, TDF had superior antiviral efficacy with a similar safety profile compared with ADV through 48 weeks.

图1 患者入组流程图
表1 患者基线人口学指标与临床指标比较(FAS集分析)
图2 HBeAg阳性患者治疗48周两组HBV DNA动态下降情况
表2 治疗48周两组患者疗效指标(FAS集分析)
图3 HBeAg阴性患者治疗48周两组HBV DNA动态下降情况
图4 HBeAg阳性患者治疗48周两组ALT动态下降情况
图5 HBeAg阴性患者治疗48周两组ALT动态下降情况
1
中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2015更新版)[J/CD]. 中华实验和临床感染病杂志:电子版,2015,9(5):570-589..
2
Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int,2016,10(1):1-98.
3
Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med,2008,359(23):2442-2455.
4
Hou JL, Gao ZL, Xie Q, et al. Tenofovir disoproxil fumarate vs adefovir dipivoxil in Chinese patients with chronic hepatitis B after 48 weeks: a randomized controlled trial[J]. J Viral Hepat,2015,22(2):85-93.
5
Yang J, Chen J, Ye P, et al. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients[J]. J Transl Med,2014,12:183.
6
Boyd A, Maylin S, Gozlan J, et al. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV[J]. Liver Int,2015,35(3):795-804.
7
Buti M, Tsai N, Petersen J, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection[J]. Dig Dis Sci,2015,60(5):1457-1464.
8
Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure[J]. J Hepatol,2008,48(5):747-755.
9
Murakami E, Tsuge M, Hiraga N, et al. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones[J]. J Infect,2016,72(1):91-102.
10
Qin B, Budeus B, Cao L, et al. The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir[J]. Antiviral Res,2013,97(2):93-100.
11
Svarovskaia ES, Curtis M, Zhu Y, et al. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen[J]. J Viral Hepat,2013,20(2):131-140.
12
Berg T, Marcellin P, Zoulim F, et al. Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection[J]. Gastroenterology,2010,139(4):1207-1217.
13
Kim JH, Ahn SH, Ko SY, et al. The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy[J]. Clin Mol Hepatol,2016,22(2):241-249.
14
Kim JH, Jung SW, Byun SS, et al. Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice[J]. Int J Clin Pharm,2015,37(6):1228-1234.
15
Bunchorntavakul C, Taweewattanakitbavorn V, Atsawarungruangkit A. Bone mineral density and renal function in chronic hepatitis B patients receiving nucleotide versus nucleoside analogs: a pilot prospective study[J]. J Med Assoc Thai,2016,99(Suppl 2):S1-S8.
16
Carnovali M, Banfi G, Mora S, et al. Tenofovir and bone: age-dependent effects in a zebrafish animal model[J]. Antivir Ther,2016. [Epub ahead of prin]
17
Shin JH, Kwon HJ, Jang HR, et al. Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents[J]. Medicine (Baltimore),2016,95(1):e2400.
18
Marcellin P, Buti M, Krastev Z, et al. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate[J]. J Hepatol,2014,61(6):1228-1237.
19
Marcellin P, Ahn SH, Ma X, et al. Combination of tenofovir disoproxil fumarate and Peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J]. Gastroenterology,2016,150(1):134-144.
20
Atay K, Hatemi, Canbakan B,et al. Five-year results of oral antiviral therapy in HBeAg-negative chronic Hepatitis B[J]. Turk J Gastroenterol,2016,27(3):279-283.
[1] 周涵, 武胡雯, 张培深, 邓晗彬, 范闻轩, 李嘉诚, 程少文. 蛋白质组学在慢性难愈合创面研究中的应用进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 536-540.
[2] 王小琴, 汪丽, 崔建英. 无张力疝修补术治疗慢性肾功能衰竭合并腹股沟疝患者的疗效[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 538-542.
[3] 闫亚飞, 范学圣, 张舰, 吴勇. 经腹腹膜前疝修补术治疗复发腹股沟疝的临床效果[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(05): 552-556.
[4] 刘敏思, 李荣, 李媚. 基于GGT与Plt比值的模型在HBV相关肝细胞癌诊断中的作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 831-835.
[5] 程柏凯, 杨光. 高胰岛素-正葡萄糖钳夹技术评估慢性肾脏病患者胰岛素抵抗的研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 334-339.
[6] 陈意志. 核磁共振钆造影剂导致的肾源性系统性纤维化[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 358-358.
[7] 冯熔熔, 苏晓乐, 王利华. 慢性肾脏病患者并发心血管疾病相关生物标志物研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 273-278.
[8] 郭俊楠, 林惠, 任艺林, 乔晞. 氨基酸代谢异常在急性肾损伤向慢性肾脏病转变中的作用研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 283-287.
[9] 董佳, 王坤, 张莉. 预后营养指数结合免疫球蛋白、血糖及甲胎蛋白对HBV 相关慢加急性肝衰竭患者治疗后预后不良的预测价值[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(06): 555-559.
[10] 贾玲玲, 滕飞, 常键, 黄福, 刘剑萍. 心肺康复在各种疾病中应用的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 859-862.
[11] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[12] 闫维, 张二明, 张克, 安欣华, 向平超. 北京市石景山区40岁及以上居民早期慢性阻塞性肺疾病异质性及影响因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 533-540.
[13] 黄圣楷, 许斌, 苏健, 孙龙. 海南省2010~2020年乙型肝炎流行趋势的时间序列分析及预测[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 555-561.
[14] 王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
[15] 奚培培, 周加军. 慢性肾脏病患者肌少症机制和诊治的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 491-495.
阅读次数
全文


摘要